S-8 EX-FILING FEES 0000906709 Fees to be Paid N/A 0000906709 1 2026-10-19 2026-10-19 0000906709 2026-10-19 2026-10-19 iso4217:USD xbrli:pure xbrli:shares

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-8

Nektar Therapeutics

Table 1: Newly Registered Securities

                                       
Security Type   Security Class Title   Notes   Fee Calculation
Rule		   Amount Registered   Proposed Maximum Offering
Price Per Unit		   Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                       
Equity   Common Stock, $0.0001 par value per share   (1)   Other   250,000   $ 36.83   $ 9,207,500.00   0.000087   $ 801.06
                                       
Total Offering Amounts:   $ 9,207,500.00         801.06
Total Fee Offsets:               0.00
Net Fee Due:             $ 801.06

 

__________________________________________
Offering Note(s)

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share (the “Common Stock”), which become issuable under the Nektar Therapeutics 2025 Inducement Plan, as amended, (the “Plan”) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of the Registrant’s outstanding shares of common stock.

The amount to be registered represents 250,000 additional shares of Common Stock issuable under the Plan, pursuant to an amendment approved by the Board of Directors of the Registrant on September 23, 2026.

The proposed maximum offering price per unit is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act on the basis of the average of the high and low sales prices of the Common Stock as reported on the Nasdaq Capital Market on October 16, 2026.